2009
Merck and Schering-Plough agreed to a $41 billion merger in 2009, structured as a reverse merger with Schering-Plough as the legal acquirer.
“It's 2009. Merck and Shering Plough agree to a massive $41 billion mega merger.”
Topic
12 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
2009
Merck and Schering-Plough agreed to a $41 billion merger in 2009, structured as a reverse merger with Schering-Plough as the legal acquirer.
“It's 2009. Merck and Shering Plough agree to a massive $41 billion mega merger.”
2011
Merck began Keynote 001, a 30-patient phase one pembrolizumab study in melanoma, in 2011.
“In 2011, they initiated a small 30-patient phase one study focused on melanoma. They call it Keynote 001.”
2013
Worldwide sales of Merck's asthma drug Singulair fell 75% year over year by the first quarter of 2013 after its patent expired.
“By the first quarter of 2013, worldwide sales had collapsed 75 % year over year.”
2013
Under Roger Perlmutter, more than half of Merck's drug development budget was redirected to pembrolizumab, funding over 700 clinical trials.
“ultimately more than half of Merck's entire drug development budget gets redirected towards pembrolizumab, ultimately fueling over 700 clinical trials across dozens of cancer types.”
2013
Merck received FDA Breakthrough Therapy Designation for pembrolizumab in January 2013, which BMS's nivolumab did not have.
“Because of that early melanoma data with Pembrolizumab, Merck applied for and got the breakthrough designation in January 2013, a few months before Perimuter arrived on site.”
2018
In 2018 Merck published Keynote 189, which combined Keytruda with chemotherapy in lung cancer patients regardless of PD-L1 status.
“In 2018, Merck publishes the results of their combination trial, Keynote 189. They gave Keytruda and standard of care chemotherapy to all comers”
2023
In a phase two study, the highest dose of Merck's oral PCSK9-targeting drug reduced LDL cholesterol by about 60%.
“basically, the highest dose reduced patients' LDL or bad cholesterol by about 60 % with a pill.”
2023
Merck was expected to start a phase three trial of its oral PCSK9 drug in the second half of 2023, according to Meg Terrell.
“Merck is expected to start that in the second half of 2023”
2025
Merck launched Keytruda Qlex, a subcutaneous version of Keytruda, in late 2025.
“In late 2025 last year, Merck launched Keytruda Qlex, which is a subcutaneous version of the drug.”
2028
Keytruda's original patents begin expiring in 2028, with eight pembrolizumab biosimilars said to be in development.
“The original patents for Keytruda begin expiring in 2028, and there are already eight different Pembro biosimilars in development ready to jump in when it finally does.”
Undated
Merck's Keynote 001 data showed about a 45% response rate in patients with PD-L1 expression above 50% versus about 10% in those below 1%.
“They discovered that patients with expression above 50 % had a roughly 45 % response rate, while patients below 1 % PD-L1 responded at only about a 10 % rate.”
Undated
BMS's all-comers first-line lung cancer trial Checkmate 26 had a hazard ratio of 1.02 and failed, while Merck's enriched Keynote 24 trial succeeded.
“BMS's all comers trial, Checkmate 26, produced a hazard ratio of 1.02. It showed absolutely zero benefit and completely failed.”
Episodes